Firm's proxy statement for April 26 annual meeting details resignation packages for three of the recently departed senior execs: President George Ebright ( $ 1.16 mil. plus approximately $ 250,000 annual retirement benefits); SK&F R&D President Stanley Crooke ( $ 620,000, a $ 310,000 three-year interest-free loan, $ 25,000 per year for two years consulting, and $ 250,000 each year for four years "to support Dr. Crooke's ongoing research"); SK&F Labs President James Cavanaugh ( $ 540,000). Part of the cost of the severance packages was defrayed by a cut in the bonus to SmithKline Chairman Henry Wendt. The chairman received a $ 750,000 bonus for 1987 and no bonus in 1988.
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”